Genexine Inc.and ToolGen Inc.’s merger plan has met a final unexpected obstacle – the bearish turn of the stock market – and failed to go through despite high expectations in the South Korean pharma industry that it would create a large biotech group with a combination of immunotherapy and DNA vaccine technologies as well as genome editing technology.
After announcing the merger in June, the two companies held shareholder meetings in July and approved the plan